N4-{tert-butyl}-2-chloroquinoline-3,4-diamine | 879000-84-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N4-{tert-butyl}-2-chloroquinoline-3,4-diamine
• 英文别名: N4-(tert-butyl)-2-chloroquinoline-3,4-diamine；4-N-tert-butyl-2-chloroquinoline-3,4-diamine
• CAS: 879000-84-7
• 化学式: C₁₃H₁₆ClN₃
• 分子量: 249.743
• InChiKey: DTDZITAPQZAKIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N4-{tert-butyl}-2-chloroquinoline-3,4-diamine 在 盐酸 、 氨 作用下， 以 甲苯 为溶剂， 反应 0.5h， 生成 3H-咪唑并[4,5-c]喹啉-4-氨
  参考文献：
  名称：

  Synthesis and Structure−Activity-Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production

  摘要：

  1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogues as potential antiviral agents. While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. We have determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, we found that the compounds also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

  DOI：

  10.1021/jm049211v
• 作为产物：
  描述：

  2,4-二氯-3-硝基喹啉 在 platinum on activated charcoal 氢气 、 magnesium sulfate 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 N4-{tert-butyl}-2-chloroquinoline-3,4-diamine
  参考文献：
  名称：

  Synthesis and Structure−Activity-Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production

  摘要：

  1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogues as potential antiviral agents. While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. We have determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, we found that the compounds also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

  DOI：

  10.1021/jm049211v

文献信息

• 2-Amino 1H-Imidazo Ring Systems and Methods
  申请人：Kshirsagar Tushar A.

  公开号：US20090023720A1

  公开（公告）日：2009-01-22

  1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明揭示了在2-位置具有氨基取代基的咪唑环系统（例如咪唑吡啶，咪唑喹啉，咪唑萘啉，6,7,8,9-四氢咪唑喹啉和咪唑萘啉），含有这些化合物的制药组合物，制备这些化合物的方法，中间体以及这些化合物作为免疫调节剂的用途，用于调节动物细胞因子生物合成以及治疗包括病毒和肿瘤性疾病在内的疾病的方法。
• 2-amino 1H-in-imidazo ring systems and methods
  申请人：3M Innovative Properties Company

  公开号：US08143270B2

  公开（公告）日：2012-03-27

  1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明公开了在2位具有氨基取代基的1H-咪唑环系（例如咪唑吡啶、咪唑喹啉、咪唑萘啉、6,7,8,9-四氢咪唑喹啉和咪唑萘啉）及其制药组合物、制备上述化合物的方法、中间体以及这些化合物的用途，包括作为免疫调节剂，调节动物的细胞因子生物合成，用于治疗包括病毒和肿瘤疾病在内的疾病。
• [EN] 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS<br/>[FR] SYSTEMES CYCLIQUES DE 2-AMINO 1H-IMIDAZO ET PROCEDES CORRESPONDANTS
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2006029115A3

  公开（公告）日：2007-06-28
• Synthesis and Structure−Activity-Relationships of 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolines That Induce Interferon Production
  作者：John F. Gerster、Kyle J. Lindstrom、Richard L. Miller、Mark A. Tomai、Woubalem Birmachu、Shannon N. Bomersine、Shiela J. Gibson、Linda M. Imbertson、Joel R. Jacobson、Roy T. Knafla、Peter V. Maye、Nickolas Nikolaides、Folakemi Y. Oneyemi、Gwen J. Parkhurst、Sharon E. Pecore、Michael J. Reiter、Lisa S. Scribner、Tracy L. Testerman、Natalie J. Thompson、Tammy L. Wagner、Charles E. Weeks、Jean-Denis Andre、Daniel Lagain、Yvon Bastard、Michel Lupu

  DOI：10.1021/jm049211v

  日期：2005.5.1

  1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogues as potential antiviral agents. While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. We have determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, we found that the compounds also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.